Enimmune Corporation (TPEX:6564)
Taiwan
· Delayed Price · Currency is TWD 18.70
-0.65 (-3.36%)
Apr 29, 2026, 1:24 PM CST
Enimmune Revenue
In the year 2025, Enimmune had annual revenue of 48.19M TWD with 20.74% growth. Enimmune had revenue of 25.55M in the half year ending December 31, 2025, a decrease of -16.21%.
Revenue
48.19M
Revenue Growth
+20.74%
P/S Ratio
28.36
Revenue / Employee
n/a
Employees
38
Market Cap
1.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19M | 8.28M | 20.74% |
| Dec 31, 2024 | 39.92M | -3.58M | -8.23% |
| Dec 31, 2023 | 43.49M | -144.92M | -76.92% |
| Dec 31, 2022 | 188.42M | 78.59M | 71.56% |
| Dec 31, 2021 | 109.82M | 86.95M | 380.08% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Abnova (Taiwan) | 351.30M |
| Meribank Biotech | 471.76M |
| NeoCore Technology | 244.66M |
| GenMont Biotech Incorporation | 401.23M |
| GeneReach Biotechnology | 232.74M |
| Holy Stone Healthcare | 47.51M |
| Level Biotechnology | 736.59M |